

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Qyuns Therapeutics Co., Ltd.**  
**江蘇荃信生物醫藥股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*  
**(Stock Code: 2509)**

## **ACCEPTANCE BY THE CSRC OF APPLICATION FOR THE COMPANY'S H SHARE FULL CIRCULATION PLAN**

This announcement is made by Qyuns Therapeutics Co., Ltd. (the "**Company**") on a voluntary basis.

The Company is pleased to announce that the China Securities Regulatory Commission (中國證券監督管理委員會) (the "**CSRC**") has recently accepted the Company's application for the proposed implementation of the H share full circulation to the CSRC on behalf of certain shareholders of the Company. Pursuant to the relevant application documents, the Company has applied for the conversion of the 17,322,400 domestic shares in issue held by such shareholders of the Company into H shares and listing on The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**") (the "**Conversion and Listing**"), representing approximately 7.80% of the total issued share capital of the Company as at the date of this announcement.

Upon completion of the H share full circulation, all domestic shareholders participating in the H share full circulation will still be required to fulfil the share lock-up undertaking in accordance with the requirements of the Rules Governing the Listing of Securities on the Stock Exchange (the "**Listing Rules**") and applicable laws and regulations.

As at the date of this announcement, details of the implementation plan for the Conversion and Listing have not been finalized. The Company will make further announcement(s) on the progress of the Conversion and Listing in accordance with the requirements of the Listing Rules and applicable laws and regulations.

**The Conversion and Listing is also subject to other relevant procedures as required by the CSRC, the Stock Exchange and other relevant domestic and overseas regulatory authorities. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company. Further announcement(s) will be made to disclose any material updates and progress in respect to the H Share Full Circulation and the Conversion and Listing in accordance with the Listing Rules and other applicable laws and regulations as and when appropriate.**

By order of the Board  
**Qyuns Therapeutics Co., Ltd.**  
**Qiu Jiwan**

*Chairman of the Board and Executive Director*

Hong Kong, October 28, 2024

*As at the date of this announcement, the board of directors of the Company comprises Mr. Qiu Jiwan as chairman and executive director, Mr. Wu Yiliang and Mr. Lin Weidong as executive directors, Mr. Yu Xi, Mr. Wu Zhiqiang and Dr. Xue Mingyu as non-executive directors, and Dr. Zou Zhongmei, Dr. Ling Jianqun and Mr. Fung Che Wai, Anthony as independent non-executive directors.*